The genetic evolution of melanoma from precursor lesions

New England Journal of Medicine

Volumn 373, Issue 20, 2015, Pages 1926-1936

  Shain, A Hunter ^a,b   Yeh, Iwei ^a,b   Kovalyshyn, Ivanka ^c   Sriharan, Aravindhan ^d   Talevich, Eric ^a,b   Gagnon, Alexander ^a,b   Dummer, Reinhard ^e   North, Jeffrey ^a   Pincus, Laura ^a   Ruben, Beth ^a   Rickaby, William ^g   D'Arrigo, Corrado ^f   Robson, Alistair ^g   Bastian, Boris C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ORLANDO HEALTH   (United States)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f DORSET COUNTY HOSPITAL   (United Kingdom)

^g ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; BRAF GENE; CANCER GROWTH; CDKN2A GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE DOSAGE; GENE EXPRESSION; GENE INACTIVATION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MELANOMA; ONCOGENE N RAS; PATHOGENESIS; PRIORITY JOURNAL; PTEN GENE; TUMOR SUPPRESSOR GENE; ADVERSE EFFECTS; DISEASE COURSE; DNA SEQUENCE; GENETICS; MOLECULAR EVOLUTION; MUTATION; PATHOLOGY; PIGMENTED NEVUS; POINT MUTATION; SKIN TUMOR; ULTRAVIOLET RADIATION;

DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; EVOLUTION, MOLECULAR; HUMANS; MELANOMA; MUTATION; NEVUS, PIGMENTED; POINT MUTATION; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 84946887722     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1502583     Document Type: Article

References (36)

1. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457: 599-602.
2. Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 2014; 5: 3116.
3. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19-20.
4. Carr J, Mackie RM. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 1994; 131: 72-7.
5. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 2014; 9: 239-71.
6. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191-9.
7. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-63.
8. Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012; 44: 1006-14.
9. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339: 959-61.
10. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339: 957-9.
11. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47
12. Harbour JW, Roberson EDO, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 2013; 45: 133-5.
13. Martin M, Maßhöfer L, Temming P, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 2013; 45: 933-6.
14. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One 2013; 8(1): e55119.
15. Duffy K, Grossman D. The dysplastic nevus: from historical perspective to management in the modern era. Part I: historical, histologic, and clinical aspects. J Am Acad Dermatol 2012; 67(1); 1.e1-1.e16.
16. Kerick M, Isau M, Timmermann B, et al. Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics 2011; 4: 68.
17. Palescandolo E, Jones R, Raza A, et al. Can DNA from archived formalin-fixed paraffin embedded (FFPE) cancer tissues be used for somatic mutation analysis in next generation sequencing. Cancer Res 2012; 72: Suppl: 3178. abstract.
18. Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2: 82-93.
19. Raterman D, Jefferson K, Wendt J, Brockman M, Burgess D. Target enrichment protocol for preparing formalinfixed paraffin embedded (FFPE) tissue samples for next-generation sequencing. SeqCap EZ Library: application note. 2013 (http://www.nimblegen.com/products/lit/07180748001-FFPE-ApplicationNote-12092013.pdf).
20. Won HH, Scott SN, Brannon AR, Shah RH, Berger MF. Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. J Vis Exp 2013; 80: e50710.
21. Hedegaard J, Thorsen K, Lund MK, et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS One 2014; 9(5): e98187.
22. Talevich E, Shain AH, Bastian BC. CNVkit: copy number detection and visualization for targeted sequencing using offtarget reads. BioRxiv, 2014 (http://biorxiv.org/content/early/2014/10/29/010876).
23. Landi MT, Bauer J, Pfeiffer RM, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006; 313: 521-2.
24. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008; 5(6): e120.
25. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-46.
26. Phadke PA, Zembowicz A. Blue nevi and related tumors. Clin Lab Med 2011; 31: 345-58.
27. Chen LL, Jaimes N, Barker CA, Busam KJ, Marghoob AA. Desmoplastic melanoma: a review. J Am Acad Dermatol 2013; 68: 825-33.
28. Shain AH, Garrido M, Botton T, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet 2015 September 7 (Epub ahead of print).
29. Rivers JK. Is there more than one road to melanoma? Lancet 2004; 363: 728-30.
30. Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95: 806-12.
31. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95: 1878-90.
32. Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WH Jr. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 1980; 46: 1787-94.
33. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA 1997; 277: 1439-44.
34. Goldgar DE, Cannon-Albright LA, Meyer LJ, Piepkorn MW, Zone JJ, Skolnick MH. Inheritance of nevus number and size in melanoma and dysplastic nevus syndrome kindreds. J Natl Cancer Inst 1991; 83: 1726-33.
35. Gorgoulis VG, Vassiliou L-VF, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907-13.
36. MacKie RM, English J, Aitchison TC, Fitzsimons CP, Wilson P. The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol 1985; 113: 167-74.